Pitching Women's Health

I spent a year as fractional Director of Product at FLUXX, a menopause startup, and part of that work was getting the founder ready to raise. She was a first-time founder, a clinician by training, with a real product and real early traction. What she didn't have yet was a deck that spoke investor instead of academic.

That gap is the whole game in women's health. The science is often the easy part. The pitch is where founders from a clinical or research background lose the room. Here's what I tell them.

Lead with the patient's problem, not the disease

Academic talks open with background: the biology, the mechanism, the literature. A pitch can't. Investors don't need a lecture on the endocrinology of menopause. They need to feel the problem a patient, a clinician, or a payer has right now, and how big it is.

So cut the disease background to a line. Open with the human pain and the size of it, the population numbers, and what treatments already exist. The first thing an investor wants to know is "compared to what, and who's underserved?" The scientific-founder trap is dumping preliminary data into the deck. Investors glaze over, and nobody wants to feel stupid in a pitch.

Show that people will actually use it

In consumer software, traction is downloads. In health, it's adoption, and adoption is harder to prove. Investors want to believe two things: that clinicians and patients will use this when it ships, and that it can become a standard of care.

So show the evidence you have. Beta users, completed assessments, engagement rates, design partners, a waitlist. Real usage numbers answer the will-they-use-it question better than any market-size slide.

Name the reimbursement path

This is the slide clinical founders skip and investors look for. Will this cost more or less than current care? How does it get paid for, by insurers, by employers, out of pocket? You don't need it fully solved. You need to show you know it's the question and have a credible answer.

Your advisory board is a proof point, not decoration

It's an open secret in life-science investing: investors read your clinical advisory board as access. Access to trials, to networks, to credibility you can't buy. If respected clinicians back you, that belongs early and loud, not buried in an appendix. If they don't yet, building that board is some of the highest-leverage fundraising work you can do.

You don't have to give it all away

Here's the part founders in women's health most often miss: venture money isn't the only money, and it's the most expensive kind. Before you trade equity, look at the capital that doesn't cost you ownership:

• Non-dilutive grants. NIH SBIR/STTR for R&D-heavy validation, with BARDA, CDMRP, and ARPA-H alongside.
• Philanthropic capital. The Gates Foundation and HHS increasingly fund maternal, reproductive, and diagnostic-access work.
• Revenue-based financing, corporate partnerships, and early pilots, for working capital without dilution.
• Angel checks, often via SAFE, from people with personal conviction in the space. In underserved sectors like women's health, mission alignment is real and worth seeking out.

The strongest raises stack these. A grant funds the science, a pilot proves the model, and angels bridge to the round, so by the time you take VC money, you give up less of the company to get it.

The pitch is the product

The same note I'd give about any deck, and the one behind every note I leave on a pitch deck: investors aren't grading your science. They're deciding whether this becomes a business people pay for. Lead with the problem, prove people will use it, name how it gets paid for, and don't give away more of your company than you have to.

Raising for a health product and want a read on your deck before investors get one? Let's talk.